ClinicalTrials.gg
Not yet recruitingNCT06760533Updated Mar 5, 2026

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

An Early Phase 1 interventional study of Psilocybin 25 mg and Psychotherapy Treatment Session in IBS - Irritable Bowel Syndrome, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by NYU Langone Health · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.

Planned enrollment
260th of 287
10 · median 61
Started
2026
with 17 others
Phase 1
18 of 344
3 open now
Primary completion
2026-12
later than 15 of 48 live
Registered
319th of 344
by date

Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 260th largest by planned enrollment of the 287 interventional ones that give a count, is one of 18 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 15 of the 48 other live ones, and was the 319th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Irritable Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session with single 25 mg oral "high" dose of psilocybin or a single 100 mg dose of niacin (active placebo) and attend 4 post-therapy integration sessions.

03

Conditions studied

  • IBS - Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe IBS patients meeting Rome IV criteria. Severe IBS is defined by IBS-SS >300, or one or more emergency room (ER) visit for abdominal pain in the last year.
  • Experiencing persistent IBS symptoms despite pharmacologic therapy
  • Have an identified support person
  • Agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing
  • Participants of must agree to practice an effective means of throughout the duration of the study.
  • Participants must agree to send outside medical records in order for the study team to verify eligibility.

Exclusion criteria

Exclusion Criteria:

  • Unstable medical conditions or serious abnormalities on complete blood count, chemistries, or that in the opinion of the study physician would preclude safe participation in the trial. Some examples include:

    • Congestive heart failure
    • arrhythmias (e.g.,
    • Ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., interval > 450)
    • Recent acute myocardial infarction or
    • Evidence of ischemia (in the last year)
    • Malignant hypertension
    • Congenital long QT syndrome
    • History of valvular heart disease
    • Acute renal failure
    • Moderate to Severe hepatic impairment ( class B and C).
    • Respiratory failure
    • Recent stroke (\< 1 year from signing of consent)
    • Laboratory tests abnormalities ( ≥ 2X (ULN), aspartate aminotransferase (AST) ≥ 2X ULN, \<11.5, \<150, White Blood Cells (WBC)>10, Sodium>150, Potassium K\<3.5 or K>5.2)
    • Abnormal and clinically significant results on the physical examination (BP>139/89 mmHG), heart rate (HR)>90bpm,
    • History of Pulmonary hypertension
  • Significant central nervous system (CNS) pathology. Examples include:

    • Primary or secondary cerebral neoplasm
    • Epilepsy
    • History of stroke
    • Cerebral aneurysm
    • Dementia
    • Delirium
  • Primary psychotic or affective psychotic disorders. Examples include current or past criteria for:

    • Schizophrenia spectrum disorders
    • Schizoaffective disorder
    • Bipolar I or II disorder with psychotic features
    • Major Depressive Disorder
    • Substance induced psychotic disorders
    • Paranoid personality disorder
    • Delusional disorder
    • Borderline personality disorder
    • Any other psychotic illness
  • Family history of psychotic or serious bipolar spectrum illnesses. Examples include first-degree relative with:

    • Schizophrenia spectrum disorders
    • Schizoaffective disorder
    • Bipolar I disorder with psychotic features
    • Any other psychotic illness
  • High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation. Examples include:

    • Agitation
    • Violent behavior
  • Active substance use disorders (SUDs) defined as Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year
  • Clinically significant suicidality or high risk of completed suicide defined as:

    • 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline
    • Any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts
    • Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior
  • History of hallucinogen persisting perception disorder (HPPD)
  • Pregnancy/lactation
  • Cognitive impairment as defined by: Test (MoCA) \< 23
  • Concurrent Medications

    • Antidepressants
    • Centrally-acting serotonergic agents (e.g., monoamine oxidase inhibitors (MAOIs))
    • Antipsychotics (e.g., first and second generation)
    • Mood stabilizers (e.g., lithium, valproic acid)
    • Aldehyde dehydrogenase inhibitors (e.g., disulfiram)
    • Significant inhibitors of UGT 1A0 or UGT 1A10
    • Niacin
  • Subjects should not also be taking serotonin-acting dietary supplements (such as 5-hydroxy-tryptophan or St. John's wort)
  • Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP)
  • Have a psychiatric condition judged to be incompatible with establishment of rapport with the study therapists or safe exposure to psilocybin
  • Have any psychological or physical symptom, medication or other relevant finding prior to randomization, based on the clinical judgment of the PI or relevant clinical study staff that would make a participant unsuitable for the study.
  • Have an allergy or intolerance to either psilocybin on Niacin
  • Be enrolled in another clinical trial assessing intervention(s) for anxiety, depression, and/or existential distress (e.g., pharmacologic or psychotherapeutic interventions)
  • Are unable to provide external medical records or refuse to provide external medical records.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Intervention: Psilocybin

    Participants assigned to the intervention arm will receive psilocybin.

    Drug: Psilocybin 25 mg · Behavioral: Psychotherapy Treatment Session

  • Placebo comparator
    Control: Niacin (Placebo)

    Participants assigned to the control arm will receive a placebo (niacin).

    Behavioral: Psychotherapy Treatment Session · Drug: Niacin 100 mg

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.

  • BehavioralPsychotherapy Treatment Session

    The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.

  • DrugNiacin 100 mg

    Niacin 100 mg (placebo) administered during the psychotherapy treatment session.

06

What researchers measure

Primary outcomes

  1. Change in Abdominal Pain Severity Numeric Rating Scale (APS-NRS) Score

    A single-item assessment of abdominal pain severity in patients with IBS. Patients rate their pain severity on a scale from 0 (no pain) to 10 (worst possible pain). The total score ranges from 0-10; lower scores indicate less severe pain.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change in IBS Severity Scoring System (IBS-SSS) Score

    The IBS-SSS asks five questions about the severity of IBS symptoms over the past 10 days: abdominal pain, abdominal distention, bowel habits, and quality of life. Each question is rated on a 100-point scale. The total score is the sum of responses and ranges from 0-500; lower scores indicate less severe symptoms, where 75-175 = mild; 175-300 = moderate; and greater than 300 = severe.

    Time frame: Baseline, Week 6

  2. Hospital Anxiety and Depression Scale: Anxiety Score

    The Hospital Anxiety and Depression Scale asks 14 questions related to anxiety and depression. The Anxiety subscale comprises 7 questions; each are rated on a scale from 0-3. The total Anxiety score ranges from 0-21; higher scores indicate more severe anxiety.

    Time frame: Baseline, Week 6

  3. Hospital Anxiety and Depression Scale: Depression Score

    The Hospital Anxiety and Depression Scale asks 14 questions related to anxiety and depression. The Depression subscale comprises 7 questions; each are rated on a scale from 0-3. The total Depression score ranges from 0-21; higher scores indicate more severe depression.

    Time frame: Baseline, Week 6

  4. Number of Participants with "Type 3" or "Type 4" Rating on Bristol Stool Form Scale

    The Bristol Stool Form Scale rates the consistency of stool on the following scale: Type 1 and 2: May be difficult to pass, may indicate constipation. Type 3 and 4: Ideal stools. Type 5: Trending toward diarrhea. Type 6 and 7: Diarrhea. This measure assesses the number of participants with Type 3 and 4 (ideal) stools.

    Time frame: Baseline

  5. Number of Participants with "Type 3" or "Type 4" Rating on Bristol Stool Form Scale

    The Bristol Stool Form Scale rates the consistency of stool on the following scale: Type 1 and 2: May be difficult to pass, may indicate constipation. Type 3 and 4: Ideal stools. Type 5: Trending toward diarrhea. Type 6 and 7: Diarrhea. This measure assesses the number of participants with Type 3 and 4 (ideal) stools.

    Time frame: Month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Jan 7, 2025
StartEst.
Aug 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06760533
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Aug 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Maysaa El Zoghbi
Contact
Maysaa.ElZoghbi@nyulangone.org
216-835-7626
Aasma Shaukat
Contact
Aasma.shaukat@nyulangone.org
646-501-2906
Maysaa El Zoghbi
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion